首页 | 本学科首页   官方微博 | 高级检索  
     

中西医结合治疗难治性类风湿关节炎
引用本文:余建华,张衡. 中西医结合治疗难治性类风湿关节炎[J]. 中国实验方剂学杂志, 2010, 16(8): 201-203
作者姓名:余建华  张衡
作者单位:洛阳市第三人民医院风湿免疫科,河南,洛阳,471002
摘    要:目的 :探讨桂枝芍药知母汤联合甲氨蝶呤(MTX)和柳氮磺吡啶(SSZ)治疗难治性类风湿关节炎(RA)的疗效和安全性。 方法 :选择符合纳入标准患者81例,随机分为治疗组和对照组,治疗组40例给予桂枝芍药知母汤、MTX和SSZ治疗,对照组41例给予MTX和SSZ治疗,疗程均为12周。采用美国风湿病学会(ACR)推荐的RA疾病活动评价核心指标对两组治疗前后进行评估。 结果 :治疗后2组病情活动主要指标评分均有显著降低,治疗前后比较,差异均有非常显著性意义(P<0.01),治疗组评分降低优于对照组,差异有显著性意义(P<0.05)。治疗组达到ACR20,ACR50,ACR90疗效标准的分别为:37.5%,32.5%,20%,总有效率90%;对照组达到ACR20,ACR50,ACR90疗效标准的分别为:46.34%,19.51%,4.88%,总有效率70.73%。 结论 :桂枝芍药知母汤联合MTX和SSZ治疗难治性RA疗效明显优于MTX联合SSZ的疗效,且具有较好的安全性。

关 键 词:关节炎  类风湿  桂枝芍药知母汤  甲氨蝶呤  柳氮磺吡啶  中西医结合疗法
收稿时间:2010-03-11

Traditional Chinese and Western Medicine Treatment of Refractory Rheumatoid Arthritis Clinical Observation
YU Jian-hua and ZHANG Heng. Traditional Chinese and Western Medicine Treatment of Refractory Rheumatoid Arthritis Clinical Observation[J]. China Journal of Experimental Traditional Medical Formulae, 2010, 16(8): 201-203
Authors:YU Jian-hua and ZHANG Heng
Affiliation:Rheumatism Department , Luoyang Third People's Hospital, Luoyang 471002, China;Rheumatism Department , Luoyang Third People's Hospital, Luoyang 471002, China
Abstract:Objective: Explore the efficacy and safety of Guizhi Shaoyao Zhimutang combine methotrexate (MTX) and sulfasalazine (SSZ) on refractory rheumatoid arthritis (RA). Method: Select 81 patients met the inclusion criteria were randomly divided into two groups. Patients in treatment group ( n =40) were treated with Guizhi Shaoyao Zhimutang combine methotrexate (MTX) and sulfasalazine (SSZ). Patients in control group ( n =41) were treated with methotrexate (MTX) and sulfasalazine (SSZ). The therapeutic course was 12 weeks in both groups. Based on American college of rheumatology (ACR) recommended evaluation of RA disease activity core set of indicators to assess the two groups before and after treatment. Result: After treatment, both groups score major indicators of disease activity were significantly decreased ,before and after treatment the differences were highly statistically significant (P<0.01), the treatment group score lower than the control group, the difference was significant (P<0.05 ). The treatment group achieved ACR20, ACR50, ACR90 efficacy criteria were: 37.5%, 32.5%, 20%, with a total effective rate 90%; the control group achieved ACR20, ACR50, ACR90 efficacy criteria were: 46.34%, 19.51%, 4.88 %, the total efficiency of 70.73%. Conclusion: Guizhi Shaoyao Zhimutang combine methotrexate (MTX) and sulfasalazine (SSZ) the efficacy of the treatment of refractory rheumatoid arthritis is superior to the efficacy of methotrexate (MTX) and sulfasalazine (SSZ), and has good security.
Keywords:arthritis  rheumatoid  Guizhi Shaoyao Zhimutang  methotrexate  sulfasalazine  TCM-WM therapy
本文献已被 万方数据 等数据库收录!
点击此处可从《中国实验方剂学杂志》浏览原始摘要信息
点击此处可从《中国实验方剂学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号